Unfavorable prognoses and increased vulnerability to CRC have been associated with genetic polymorphisms in the genes that encode for the IL-17A, IL-17E, and IL-23 receptors, which are released during the development of Th17 cells. This evidence concerns the gene IL17A and colorectal carcinoma.